Eva Kiss1, Zsuzsanna Nemeth1, Magdolna Dank1
1Cancer Center, Semmelweis University, Budapest
DNA methylation is an important epigenetic regulation mechanism, which has role in gene expression, cell proliferation or maintenance of DNA integrity. Cancer is usually characterized by global hypomethylation in the genom as well as local hypermethylation in promoter regions. Nutrition is one of the most important factor which considerably influence the development and progression of cancer. Dietary methyl donors are food components, which provide methyl groups for the one-carbon metabolism supporting methylation processes.
Our aim was to examine the effect of dietary methyl donors on cell proliferation on different human cancer cell lines to investigate whether could be used as a potential complementary therapy in cancer treatment.
Panc-1 (human pancreas carcinoma) and MCF7 (human breast adenocarcinoma) cell lines were grown in 96 well plates and treated with different concentrations (1x, 10x, 20x) of methyl donors. Basal concentration (1x) was: 17 mg/L L-methionine, 9 mg/L choline chloride, 3 mg/L folic acid and 2 mg/L vitamin B12. Cell proliferation was measured by the absorbance at 490nm after 24, 48 and 72 hours using an MTS cell proliferation assay. Two-way Anova and Bonferroni posthoc test was used to compare the absorbance of the treatment groups to the controls.
Methyl donor treatments caused reduction in the absorbances in both observed cell lines. Basal and twenty times higher concentrations caused significant, dose-dependent decrease in the proliferation of Panc-1 cells (p≤0.05 and p≤0.01, respectively) at 48 hours treatment, compared to the control. In case of MCF7 cells, treatments caused dose-dependent decrease in the proliferation after 48 and 72 hours (p≤0.01 and p<0.001, respectively).
Our results indicate that methyl donor supplementation induces significant decrease in cell proliferation of Panc-1 and MCF7 tumour cells as well. Our results suggest that an appropriate dietary guidance might be an effective complementary treatment for cancer patients but need further, and more detailed investigation.
Doctoral School: Pathological Sciences
Program: Experimental Oncology
Supervisor: Magdolna Dank
E-mail address: email@example.com